The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
Other tools for assessing whether or not a person has a moderate weight or body composition include the waist-to-hip ratio, waist-to-height ratio, and body fat percentage
At low doses, this can represent a meaningful percentage of your dose
It is also suitable for researchers who want to test semaglutide before committing to a larger purchase
How the eligibility checker works The checker uses three inputs: your BMI (from your height and weight), your ethnic background, and your weight-related health conditions